Company Filing History:
2 out of 8 
2 out of 16 
1 out of 11 
Years Active: 2014-2016
Title: Innovations of Steven Geoffrey Aitken
Introduction
Steven Geoffrey Aitken is a notable inventor based in Christchurch, New Zealand. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of cysteine protease inhibitors. With a total of two patents to his name, Aitken's work has the potential to impact the treatment of various diseases.
Latest Patents
Aitken's latest patents include a novel class of macrocyclic compounds that serve as cysteine protease inhibitors. These compounds are designed to inhibit cysteine protease activity, particularly calpain activity, which is associated with several diseases. The patents also detail novel intermediates and methods for preparing these compounds, along with pharmaceutical compositions that incorporate them. This innovation holds promise for treating or preventing diseases linked to cysteine protease activity.
Career Highlights
Throughout his career, Aitken has worked with esteemed institutions such as Lincoln University and Douglas Pharmaceuticals Limited. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.
Collaborations
Some of Aitken's notable coworkers include Andrew David Abell and James Morriss Coxon. Their collaborative efforts have contributed to advancements in their respective fields.
Conclusion
Steven Geoffrey Aitken's innovative work in the development of macrocyclic cysteine protease inhibitors showcases his commitment to advancing pharmaceutical science. His contributions have the potential to lead to significant improvements in the treatment of diseases associated with cysteine protease activity.